Impact of type of thrombolytic agent on in-hospital outcomes in ST-segment elevation myocardial infarction patients in the Middle East

Ibrahim Al-Zakwani, Amr Ali, Mohammad Zubaid, Prashanth Panduranga, Kadhim Sulaiman, Ahmed Abusham, Wael Almahmeed, Ahmed Al-Motarreb, Jassim Al Suwaidi, Haitham Amin

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Little is known about the impact of thrombolytic agents on in-hospital outcomes in the Middle East. The objective of this study was to evaluate the impact of thrombolytic agents on in-hospital outcomes in ST-segment elevation myocardial infarction (STEMI) patients in six Middle Eastern countries. Gulf Registry of Acute Coronary Events was a prospective, multinational, multicentre, observational survey of consecutive acute coronary syndrome patients admitted to 65 hospitals in 2006 and 2007. Out of 1,765 STEMI patients admitted to hospitals within 12 h of symptoms onset, 25, 43, and 30% were treated with streptokinase, reteplase, and tenecteplase, respectively. Median age of the study cohort was 50 (45-59) years and majority were males (89%). The overall median symptom onset-to-presentation andmedian door-to-needle times were 130 min (65-240) and 45 min (30-75), respectively. Streptokinase patients had worse GRACE risk scores compared to patients who received fibrin specific thrombolytics. Academic hospitals and cardiologists as admitting physicians were associated with the use of fibrin specific thrombolytics. After significant covariate adjustment, both reteplase >odds ratio (OR), 0.38; 95% CI: 0.18-0.79; P = 0.009] and tenecteplase (OR, 0.30; 95% CI: 0.12-0.77; P = 0.012) were associated with lower allcause in-hospital mortality compared with streptokinase. No significant differences in other in-hospital outcomes were noted between the thrombolytic agents. In conclusion, in light of the study's limitations, fibrin specific agents, reteplase and tenecteplase, were associated with lower all-cause in-hospital mortality compared to the non-specific fibrin agent, streptokinase. However, the type of thrombolytic agent used did not influence other in-hospital outcomes.

Original languageEnglish
Pages (from-to)280-286
Number of pages7
JournalJournal of Thrombosis and Thrombolysis
Volume33
Issue number3
DOIs
Publication statusPublished - Apr 2012

Fingerprint

Middle East
Fibrinolytic Agents
Streptokinase
Fibrin
Hospital Mortality
Odds Ratio
Acute Coronary Syndrome
ST Elevation Myocardial Infarction
Needles
Registries
Cohort Studies
Physicians
tenecteplase
reteplase

Keywords

  • Hospital mortality
  • Middle East
  • Myocardial infarction
  • Reteplase
  • Streptokinase
  • Tenecteplase
  • Thrombolytic therapy

ASJC Scopus subject areas

  • Hematology
  • Cardiology and Cardiovascular Medicine

Cite this

Impact of type of thrombolytic agent on in-hospital outcomes in ST-segment elevation myocardial infarction patients in the Middle East. / Al-Zakwani, Ibrahim; Ali, Amr; Zubaid, Mohammad; Panduranga, Prashanth; Sulaiman, Kadhim; Abusham, Ahmed; Almahmeed, Wael; Al-Motarreb, Ahmed; Suwaidi, Jassim Al; Amin, Haitham.

In: Journal of Thrombosis and Thrombolysis, Vol. 33, No. 3, 04.2012, p. 280-286.

Research output: Contribution to journalArticle

Al-Zakwani, I, Ali, A, Zubaid, M, Panduranga, P, Sulaiman, K, Abusham, A, Almahmeed, W, Al-Motarreb, A, Suwaidi, JA & Amin, H 2012, 'Impact of type of thrombolytic agent on in-hospital outcomes in ST-segment elevation myocardial infarction patients in the Middle East', Journal of Thrombosis and Thrombolysis, vol. 33, no. 3, pp. 280-286. https://doi.org/10.1007/s11239-012-0698-6
Al-Zakwani, Ibrahim ; Ali, Amr ; Zubaid, Mohammad ; Panduranga, Prashanth ; Sulaiman, Kadhim ; Abusham, Ahmed ; Almahmeed, Wael ; Al-Motarreb, Ahmed ; Suwaidi, Jassim Al ; Amin, Haitham. / Impact of type of thrombolytic agent on in-hospital outcomes in ST-segment elevation myocardial infarction patients in the Middle East. In: Journal of Thrombosis and Thrombolysis. 2012 ; Vol. 33, No. 3. pp. 280-286.
@article{2d90054e6abd41c1b54f67a4423a3a1e,
title = "Impact of type of thrombolytic agent on in-hospital outcomes in ST-segment elevation myocardial infarction patients in the Middle East",
abstract = "Little is known about the impact of thrombolytic agents on in-hospital outcomes in the Middle East. The objective of this study was to evaluate the impact of thrombolytic agents on in-hospital outcomes in ST-segment elevation myocardial infarction (STEMI) patients in six Middle Eastern countries. Gulf Registry of Acute Coronary Events was a prospective, multinational, multicentre, observational survey of consecutive acute coronary syndrome patients admitted to 65 hospitals in 2006 and 2007. Out of 1,765 STEMI patients admitted to hospitals within 12 h of symptoms onset, 25, 43, and 30{\%} were treated with streptokinase, reteplase, and tenecteplase, respectively. Median age of the study cohort was 50 (45-59) years and majority were males (89{\%}). The overall median symptom onset-to-presentation andmedian door-to-needle times were 130 min (65-240) and 45 min (30-75), respectively. Streptokinase patients had worse GRACE risk scores compared to patients who received fibrin specific thrombolytics. Academic hospitals and cardiologists as admitting physicians were associated with the use of fibrin specific thrombolytics. After significant covariate adjustment, both reteplase >odds ratio (OR), 0.38; 95{\%} CI: 0.18-0.79; P = 0.009] and tenecteplase (OR, 0.30; 95{\%} CI: 0.12-0.77; P = 0.012) were associated with lower allcause in-hospital mortality compared with streptokinase. No significant differences in other in-hospital outcomes were noted between the thrombolytic agents. In conclusion, in light of the study's limitations, fibrin specific agents, reteplase and tenecteplase, were associated with lower all-cause in-hospital mortality compared to the non-specific fibrin agent, streptokinase. However, the type of thrombolytic agent used did not influence other in-hospital outcomes.",
keywords = "Hospital mortality, Middle East, Myocardial infarction, Reteplase, Streptokinase, Tenecteplase, Thrombolytic therapy",
author = "Ibrahim Al-Zakwani and Amr Ali and Mohammad Zubaid and Prashanth Panduranga and Kadhim Sulaiman and Ahmed Abusham and Wael Almahmeed and Ahmed Al-Motarreb and Suwaidi, {Jassim Al} and Haitham Amin",
year = "2012",
month = "4",
doi = "10.1007/s11239-012-0698-6",
language = "English",
volume = "33",
pages = "280--286",
journal = "Journal of Thrombosis and Thrombolysis",
issn = "0929-5305",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - Impact of type of thrombolytic agent on in-hospital outcomes in ST-segment elevation myocardial infarction patients in the Middle East

AU - Al-Zakwani, Ibrahim

AU - Ali, Amr

AU - Zubaid, Mohammad

AU - Panduranga, Prashanth

AU - Sulaiman, Kadhim

AU - Abusham, Ahmed

AU - Almahmeed, Wael

AU - Al-Motarreb, Ahmed

AU - Suwaidi, Jassim Al

AU - Amin, Haitham

PY - 2012/4

Y1 - 2012/4

N2 - Little is known about the impact of thrombolytic agents on in-hospital outcomes in the Middle East. The objective of this study was to evaluate the impact of thrombolytic agents on in-hospital outcomes in ST-segment elevation myocardial infarction (STEMI) patients in six Middle Eastern countries. Gulf Registry of Acute Coronary Events was a prospective, multinational, multicentre, observational survey of consecutive acute coronary syndrome patients admitted to 65 hospitals in 2006 and 2007. Out of 1,765 STEMI patients admitted to hospitals within 12 h of symptoms onset, 25, 43, and 30% were treated with streptokinase, reteplase, and tenecteplase, respectively. Median age of the study cohort was 50 (45-59) years and majority were males (89%). The overall median symptom onset-to-presentation andmedian door-to-needle times were 130 min (65-240) and 45 min (30-75), respectively. Streptokinase patients had worse GRACE risk scores compared to patients who received fibrin specific thrombolytics. Academic hospitals and cardiologists as admitting physicians were associated with the use of fibrin specific thrombolytics. After significant covariate adjustment, both reteplase >odds ratio (OR), 0.38; 95% CI: 0.18-0.79; P = 0.009] and tenecteplase (OR, 0.30; 95% CI: 0.12-0.77; P = 0.012) were associated with lower allcause in-hospital mortality compared with streptokinase. No significant differences in other in-hospital outcomes were noted between the thrombolytic agents. In conclusion, in light of the study's limitations, fibrin specific agents, reteplase and tenecteplase, were associated with lower all-cause in-hospital mortality compared to the non-specific fibrin agent, streptokinase. However, the type of thrombolytic agent used did not influence other in-hospital outcomes.

AB - Little is known about the impact of thrombolytic agents on in-hospital outcomes in the Middle East. The objective of this study was to evaluate the impact of thrombolytic agents on in-hospital outcomes in ST-segment elevation myocardial infarction (STEMI) patients in six Middle Eastern countries. Gulf Registry of Acute Coronary Events was a prospective, multinational, multicentre, observational survey of consecutive acute coronary syndrome patients admitted to 65 hospitals in 2006 and 2007. Out of 1,765 STEMI patients admitted to hospitals within 12 h of symptoms onset, 25, 43, and 30% were treated with streptokinase, reteplase, and tenecteplase, respectively. Median age of the study cohort was 50 (45-59) years and majority were males (89%). The overall median symptom onset-to-presentation andmedian door-to-needle times were 130 min (65-240) and 45 min (30-75), respectively. Streptokinase patients had worse GRACE risk scores compared to patients who received fibrin specific thrombolytics. Academic hospitals and cardiologists as admitting physicians were associated with the use of fibrin specific thrombolytics. After significant covariate adjustment, both reteplase >odds ratio (OR), 0.38; 95% CI: 0.18-0.79; P = 0.009] and tenecteplase (OR, 0.30; 95% CI: 0.12-0.77; P = 0.012) were associated with lower allcause in-hospital mortality compared with streptokinase. No significant differences in other in-hospital outcomes were noted between the thrombolytic agents. In conclusion, in light of the study's limitations, fibrin specific agents, reteplase and tenecteplase, were associated with lower all-cause in-hospital mortality compared to the non-specific fibrin agent, streptokinase. However, the type of thrombolytic agent used did not influence other in-hospital outcomes.

KW - Hospital mortality

KW - Middle East

KW - Myocardial infarction

KW - Reteplase

KW - Streptokinase

KW - Tenecteplase

KW - Thrombolytic therapy

UR - http://www.scopus.com/inward/record.url?scp=84871685754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871685754&partnerID=8YFLogxK

U2 - 10.1007/s11239-012-0698-6

DO - 10.1007/s11239-012-0698-6

M3 - Article

VL - 33

SP - 280

EP - 286

JO - Journal of Thrombosis and Thrombolysis

JF - Journal of Thrombosis and Thrombolysis

SN - 0929-5305

IS - 3

ER -